Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Patrono
C
C
Department of Medicine and Aging, University of Chieti G. D'Annunzio School of Medicine, Chieti, Italy. cpatrono@unich.it
Patrignani
P
P
García Rodríguez
L A
LA
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects / Q000201:enzymology; D002318:Cardiovascular Diseases / Q000453:epidemiology; D000068579:Celecoxib; D015179:Colorectal Neoplasms / Q000517:prevention & control; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D003864:Depression, Chemical; D015232:Dinoprostone / Q000096:biosynthesis; D011464:Epoprostenol / Q000096:biosynthesis; D005753:Gastric Mucosa / Q000187:drug effects; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D015994:Incidence; D007413:Intestinal Mucosa / Q000187:drug effects; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000502:physiology; D007783:Lactones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D008565:Membrane Proteins; D010437:Peptic Ulcer / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control; D011451:Prostaglandin-Endoperoxide Synthases / Q000502:physiology; D011453:Prostaglandins / Q000096:biosynthesis*; D011720:Pyrazoles; D016032:Randomized Controlled Trials as Topic; D013379:Substrate Specificity; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D013450:Sulfones; D013923:Thromboembolism / Q000453:epidemiology / Q000517:prevention & control; D013928:Thromboxane A2 / Q000096:biosynthesis; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016588:Anticarcinogenic Agents; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D011453:Prostaglandins; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D013928:Thromboxane A2; D011464:Epoprostenol; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib; D015232:Dinoprostone; D001241:Aspirin